http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109897831-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2019-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109897831-B |
| titleOfInvention | Adeno-associated virus virions with mutant capsids and uses thereof |
| abstract | The invention discloses an adeno-associated virus virion with mutant capsid and application thereof. The adeno-associated virus virions with a mutated capsid have a mutated AAV6 capsid protein, which confers enhanced infectivity of retinotropic Muller cells. Wherein the 663 th serine in the amino acid sequence of the mutant AAV6 capsid protein is mutated to leucine relative to the corresponding parental AAV6 capsid protein. The pharmaceutical composition comprises the adeno-associated virus virion and a pharmaceutically acceptable excipient. The invention obtains the specific AAV vector for efficiently transducing Muller cells by site-directed mutagenesis of the amino acids encoding AAV6 capsid, and is suitable for a method for treating retinopathy by transducing Muller cells with exogenous therapeutic genes. |
| priorityDate | 2019-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 371.